Pivotal AFFINITY DUCHENNE results showed microdystrophin expression above the prespecified threshold in 93% of evaluable participants, with preliminary functional findings favoring treatment over external controls.
Commentary|Articles|August 27, 2026
RiMS 2026: Recovery vs Compensation in MS Rehabilitation
Author(s)IJMSC staff
The 31st Annual Rehabilitation in Multiple Sclerosis Conference took up a question DMTs do not answer: when should treatment aim to restore lost function, and when should it aim to work around it?
Advertisement
Advertisement
Disease-modifying therapy (DMT) has changed the trajectory of multiple sclerosis (MS), but it has not resolved what happens to function that is already lost for people with relapsing MS or to people with progressive disease when DMT effects thin out. That gap is where rehabilitation research operates, and it was the subject of the 31st Annual Rehabilitation in Multiple Sclerosis (RiMS) Conference, held June 11-13, 2026, in Prague, Czech Republic.
Related to this article
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 16, 2026.
Three-year extension data from the phase 3 IB1001-301 trial show levacetylleucine slowed disease progression in both adults and children with Niemann-Pick disease type C.
Adults with generalized myasthenia gravis who are anti-acetylcholine receptor antibody positive now have a second self-administration option for the complement inhibitor zilucoplan.
Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Nicholas J. Maragakis, MD; and Jinsy Andrews, MD, MSc, FAAN, FANA. [LISTEN TIME: 23 minutes]
All 10 REVEAL Part A participants gained or regained at least 1 developmental milestone after a single intrathecal TSHA-102 dose, with no treatment-related SAEs reported.
Findings from the phase 3 METEOROID trial showed that satralizumab reduced the risk of relapse in patients with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease.
The phase 1 ASCEND trial is testing a single intrathecal dose of the investigational AAV9 gene therapy INS1201 in young boys with Duchenne muscular dystrophy.
Advertisement
Advertisement